Current Updates on Salpingectomy for the Prevention of Ovarian Cancer and Its Practice Patterns Worldwide

doi:10.24920/J1001-9294.2017.022

Abstract

A paradigm shift of the origin of ovarian cancer to fallopian tube has brought more focus on bilateral salpingectomy as a preventive method for ovarian cancer. Bilateral salpingectomy has shown a dramatic reduction in the risk of ovarian cancer. Bilateral salpingo-oophorectomy has been a long-used practice to prevent ovarian cancer, but it brings surgical menopause and an increased mortality rate to women undergoing such a surgery at the age of <47.5. With the prophylactic bilateral salpingectomy, however, the ovarian function remains unaltered. Recent studies have shown that prophylactic salpingectomy was helpful not only in preventing high-grade serous type ovarian cancer, but also in decreasing adnexal pathologies. With the publication of committee opinion, more practitioners have accepted this proposal, but some are more concerned about its disadvantages. This review illustrates the latest updates on salpingectomy as a preventive method for ovarian cancer, including its advantages and disadvantages, clinicians’ opinions, public opinions, so as to find out Obstetricians’ and Gynecologists’ practice pattern related to opportunistic salpingectomy worldwide.

Key words: ovarian cancer, salpingectomy, prevention, clinician opinion

Dhakal Sweta, Zheng Yun-xi, Yi Xiao-fang. Current Updates on Salpingectomy for the Prevention of Ovarian Cancer and Its Practice Patterns Worldwide[J].Chinese Medical Sciences Journal, 2017, 32(3): 185-192.

Figures/Tables 1

References 45.

1.	Mc Alpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD. Opportunistic salpingectomy: uptake, risks, complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014; 210(5): 471.e1-471.e11. doi: 10.1016/j.ajog.2014.01.003.
2	American Cancer Society: Cancer Facts and Figures 2016. Atlanta: American Cancer Society; 2016 [cited 2017 Jan 14]. Available from: .
3.	Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL.Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009; 113(4):775-82. doi: 10.1097/AOG.0b013e31819cda77.
4.	Whittemore AS, Harris R, Itnyre J.Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136(10):1212-20.
5.	Kurman RJ, Shih IeM. Molecular pathogenesis and extra ovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol 2011; 42(7):918-31. doi: 10.1016/j. humpath.2011.03.003.
6.	Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer—a proposed unifying theory. Am J Surg Pathol 2010; 34(3):433-43. doi: 10.1097/PAS.0b013e3181 cf3d79.
7.	Senturk E, Cohen S, Dottino PR, Martignetti JA.A critical re-appraisal of BRCA1 methylation studies in ovarian cancer. Gynecol Oncol 2010; 119(2):376-83. doi: 10.1016/j. ygyno.2010.07.026.
8.	Martin DC.Cancer and endometriosis: do we need to be concerned? Semin Reprod Endocrinol 1997; 15(3):319-24.
9.	Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F.Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31(2):161-9.
10.	Przybycin CG, Kurman RJ, Ronnett BM, Shih IeM, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010; 34(10):1407-16. doi: 10.1097/PAS.0b013e3181ef7b16.
11.	Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE.Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25(25):3985-90.
12.	Sehdev AS, Kurman RJ, Kuhn E, Shih IeM. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol 2010; 23(6): 844-55. doi: 10.1038/modpathol.2010.60.
13.	Kuhn E, Meeker A, Wang TL, Sehdev AS, Kurman RJ, Shih IeM. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol 2010; 34(6):829-36. doi: 10.1097/PAS.0b013e3181dcede7.
14.	Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C.The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30(2):230-6.
15.	Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM.High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 2012; 109(10):3921-6. doi: 10.1073/pnas.1117135109.
16.	Lessard-Anderson CR, Handlogten KS, Molitor RJ, Dowdy SC, Cliby WA, Weaver AL.Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol 2014; 135(3):423-7. doi: 10.1016/j.ygyno.2014.10.005.
17.	Madsen C, Baandrup L, Dehlendorff C, Kjaer SK.Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand 2015; 94(1): 86-94. doi: 10.1111/aogs.12516.
18.	Falconer H, Yin L, Gronberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Nat Cancer Inst 2015; 27: 107(2). pii: dju410. doi: 10.1093/jnci/dju410.
19.	Kwon JS, Mc Alpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM.Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol 2015; 125(2): 338-45. doi: 10.1097/AOG.0000 000000000630.
20.	Vorwergk J, Radosa MP, Nicolaus K, Baus N, Jimenez Cruz, Rengsberger M.Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate. J Cancer Res Clin Oncol 2014; 140(5):859-65. doi: 10.1007/s00432-014-1622-6.
21.	Nagle CM, Oslen CM, Webb PM, Jordan SJ, Whiteman DC, Green AC.Endometrioid and clear cell ovarian cancers—a comparative analysis of risk factors. Euro J Cancer 2008; 44(16):2477-84. doi: 10.1016/j.ejca.2008.07.009.
22.	Cibula D, Widschwendter M, Majek O, Dusek L.Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 2011; 17(1):55-67. doi: 10. 1093/humupd/dmq030.
23.	Rice MS, Hankinson SE, Tworoger SS. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the nurse’s health studies. Fertil Steril 2014; 102(1): 192-8.e3. doi: 10.1016/j.fertnstert.2014.03.041.
24.	Danis RB, Della Badia CR, Richard SD.Postpartum permanent sterilization: Could bilateral salpingectomy replace bilateral tubal ligation? J Minim Invasive Gynecol 2016; 23(6):928-32. doi: 10.1016/j.jmig.2016.05.006.
25.	Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM.Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 2013; 121(4):709-16. doi: 10.1097/AOG.0b013e3182864350.
26.	Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007; 69(11): 1074-83.
27.	Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M. Increased risk of Parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70(3):200-9.
28.	Rocca WA, Grossardt BR, Maraganore DM.The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener Dis 2008; 5(3-4):257-60.
29.	Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol 2013; 121(1):14-24. doi: .
30.	Zhao JR, Wing R, Hulka JF.Ovarian function in monkeys after bilateral salpingectomy. Int J Fertil 1984; 29(2):118-21.
31.	Halme J, Rong ZJ, Wing R, Raj MH, Raj S.The removal of fallopian tubes has no adverse effect of subsequent ovarian function in rabbits. Fertil Steril 1982; 38(5):621-4.
32.	Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D.Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol 2013; 129(3):448-51. doi: 10.1016/j.ygyno. 2013.03.023.
33.	Findley AD, Siedhoff MT, Hobbs KA, Steege JF, Carey ET, McCall CA. Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. Fertil Steril 2013; 100(6): 1704-8. doi: 10.1016/j.fertnstert.2013.07.1997.
34.	Atalay MA, Cetinkaya Demir B, Ozerkan K.Change in the ovarian environment after hysterectomy with bilateral salpingectomy: is it the technique or surgery itself? Eur J Obstet Gynecol Reprod Biol 2016; 204:57-61. doi: 10. 1016/j.ejogrb.2016.07.483.
35.	Dar P, Sachs GS, Strassburger D, Bukovsky I, Arieli S.Ovarian function before and after surgery in artificial reproductive technology patients. Hum Reprod 2000; 15(1):142-4.
36.	Qin F, Du DF, Li XL.The effect of salpingectomy on ovarian reserve and ovarian function. Obstet Gynecol Surv 2016; 71(6): 369-76. doi: 10.1097/OGX.0000000000000323.
37.	Kang JH, Nam SH, Song T, Kim WY, Lee KW, Kim KH.Public perception of risk-reducing salpingectomy for preventing ovarian cancer. Obstet Gynecol Sci 2015; 58(4):284-8. doi: 10.5468/ogs.2015.58.4.284.
38	The Society of Gynecologic Oncology of Canada. GOC statement regarding salpingectomy and ovarian cancer prevention. 2011 [cited 2017 May 9]. Available from: .
39.	Committee on Gynecologic Practice. Committee Opinion No. 620: Salpingectomy for Ovarian Cancer Prevention. Obstet Gynecol 2015; 125(1):279-81. doi: 10.1097/01. AOG.0000459871.88564.09.
40.	Gill Se, Mills BB.Physician opinions regarding elective bilateral salpingectomy with hysterectomy and for sterilization. J Minim Invasive Gynecol 2013; 20(4):517-21. doi: 10.1016/j.jmig.2013.02.010.
41.	Reade CJ, Finlayson S, McAlpine J, Tone AA, Fung-Kee-Fung, Ferguson SE. Risk-reducing salpingectomy in Canada: a survey of obstetrician-gynecologists. J Obstet Gynaecol Can 2013; 35(7):627-34. doi: 10.1016/S1701-2163(15)30894-X.
42.	Kapurubandara S, Qin V, Gurram D, Anpalagan A, Merkur H, Hogg R.Opportunistic bilateral salpingectomy during gynecological surgery for benign disease: a survey of current Australian practice. Aust N Z J Obstet Gynaecol 2015; 55(6):606-11. doi: 10.3802/jgo.2017.28.e52.
43.	Venturella R, Rocca M, Lico D, Trapasso S, Di Cello A, Gizzo S.Prophylactic bilateral salpingectomy for the prevention of ovarian cancers: What is happening in Italy? Eur J Cancer Prev 2016; 25(5):410-5. doi: 10.1097/CEJ. 0000000000000191.
44.	Garcia C, Martin M, Tucker LY, Lyon L, Armstrong MA, McBride-Allen S. Experience with opportunistic salpingectomy in a large, community based health system in United States. Obstet Gynecol 2016; 128(2):277-83. doi: 10.1097/AOG.0000000000001531.
45.	Mikhail E, Salemi JL, Wyman A, Salihu HM, Imudia AN, Hart S. Trends of bilateral salpingectomy during vaginal hysterectomy with and without laparoscopic assistance performed for benign indications in United States. J Minim Invasive Gynecol 2016; 23(7):1063-9,e1. doi: 10.1016/j.jmig.2016.07.009.

References	Year	Region	Clinicians who responded the survey (n)	Clinicians incorporated BS (%)	BS performed to reduce risk of ovarian cancer (%)	Clinicians refusing to conduct BS (%)	Reasons for refusal to perform BS
Gill et al⁴⁰	2013	US	234	54.3	75	45.5	69.4%-no benefit
Reade et al⁴¹	2013	Canada	192	45	90	55	51%-no benefit
Kapurubandars et al⁴²	2015	Australia	382	70	90	30	36%-insufficient evidence to show benefit
Venturella et al⁴³	2016	Italy	479	81.97	88	18.03	54.65%-no benefit
Garcia et al⁴⁴	2016	US	249	86	NA	14	36%-difficulty in accessing fallopian tube

[1]	Chen Xu, Huo Xiaofei, Wu Zhe, Lu Jingjing. Advances of Artificial Intelligence Application in Medical Imaging of Ovarian Cancers [J]. Chinese Medical Sciences Journal, 2021, 36(3): 196-203.
[2]	Yan Cai, Chun-jie Hu, Jia Wang, Ze-hua Wang. Influence of Deleted in Colorectal Carcinoma Gene on Proliferation of Ovarian Cancer Cell Line SKOV-3 In Vivo and In Vitro [J]. Chinese Medical Sciences Journal, 2011, 26(3): 175-181.

Early edition

Current issue

Archive

Specialties & Topics

Author center

Reviewer center